Genetic Signatures signs up
Wednesday, 22 October, 2008
Privately held Sydney biotech Human Genetic Signatures has signed a licensing agreement with US diagnostics specialist ProGen Tech to develop assays for pathogens such as MRSA and Clostridium difficile.
The assays will be integrated into ProGen Tech’s Entura nucleic acid purification system.
Human Genetic Signatures’ technology is called 3base, which is designed to simplify the genomes of microbial targets to aid detection. The company has also developed a DNA methylation analysis methodology called MethylEasy.
ProGen Tech hopes to present manual assays to the US FDA next year, followed by a fully automated version in 2010.
The equipment is aimed at the molecular and clinical diagnostics markets.
mRNA therapy found to prevent recurrence of melanoma
Merck and Moderna have announced positive topline results from their Phase 3 trial of a...
A high-performance method for CRISPR off-target nomination
A new study provides evidence that can help gene editing developers prioritise biologically...
High doses of fertility drug linked to pregnancy risks
High doses of clomiphene citrate, accumulated over multiple fertility treatment cycles, could...
